PICO Portalanswers from OpenAlex

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations

PaperCitations, authors & open-access status

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations is a paper indexed in PICO Portal from OpenAlex.

How many citations does First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations have?

PICO Portalcitation count

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations has 84 citations in the OpenAlex counts PICO Portal stores.

When was First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations published?

PICO Portalyear

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations has 2023 year in the PICO Portal index.

Open the OpenAlex record →

What is the open-access status of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations?

PICO Portaloa status

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations has green oa status in the PICO Portal index.

Open the OpenAlex record →

What is the DOI of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations?

PICO Portaldoi

The DOI for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations is on the source record.

Open the DOI →

What is the PMID of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations?

PICO Portalpmid

The PMID for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations is on the source record.

Open the PMID →

What is the OpenAlex record for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations?

PICO Portalopenalex

The OpenAlex for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations is on the source record.

Open the OpenAlex →

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations

How many citations does First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations have?

When was First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations published?

What is the open-access status of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations?

What is the DOI of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations?

What is the PMID of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations?

What is the OpenAlex record for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations?

Related on PICO Portal